---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-041805"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:18:29.076662+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech Q3 net loss $9.0M; Phase 2 mOS 39.3 months; seeks accelerated approval

## Summary
- Q3 net loss $9.0M ($0.19/share) vs $10.7M ($0.29) YoY; R&D expenses down to $4.6M.
- Cash $26.2M at Sep 30, 2025 vs $41.7M Dec 2024; raised ~$5.3M on Nov 12 stock/warrant sale.
- VERSATILE-002 Phase 2 complete: mOS 39.3 months, PFS 6.3 months in CPS≥1 HNSCC patients.
- Plans to amend VERSATILE-003 Phase 3 to seek accelerated approval with PFS as surrogate endpoint.
- Colorectal cancer cohort of PDS01ADC met Stage 2 expansion criteria (≥6 of 9 objective responses).

## SEC filing metadata
- accession: 0001140361-25-041805
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036125041805/0001140361-25-041805-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036125041805/ef20058907_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-041805
- JSON: https://secwatch.observer/filing/0001140361-25-041805.json
- Plain text: https://secwatch.observer/filing/0001140361-25-041805.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.